engleski

SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints

Taken together, this work, based on high-quality randomized trial data, showed that the risk of urinary tract infections is similar among heart failure patients assigned to SGLT2 inhibitor compared to those assigned to placebo, although this might be biased by the inadequate definitions and lack of systematic registration of these events in most of the examined trials. These findings provide important safety reassurance for patients with heart failure as well as for practicing cardiologists and other prescribers of this class of drugs.

SGLT2 ; sodium glucose co-transporter 2 inhibitors ; heart failure ; sotagliflozin ; empagliflozin ; dapagliflozin ; canagliflozin ; HFrEF ; HFpEF ; heart failure with reduced ejection fraction ; heart failure with preserved ejection fraction ; meta-analysis ; UTI ; urinary tract infections

nije evidentirano